Is it all bad news in the bear market? Not necessarily.

After a tumultuous couple of years, many biotechs are looking for signs of improvement in 2023. After all, the biotech sector felt the market pain acutely, particularly over the last 18 months: 2022 marked the longest period of net negative performance for biotech stocks, with the SPDR S&P Biotech ETF XBI extending net losses over a 70-week period. 

But things are looking up: the XBI was 7% up in January of this year, and investor sentiment seems to be improving.

Biotechs can look forward to some upward momentum if they take the right strategic steps now. In this podcast, Sara Michelmore and Karen Sharma from MacDougall Advisors share what biotechs can do to position themselves for this market swing. 

See omnystudio.com/listener for privacy information.